Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Sep 15;11(5):648-654.
doi: 10.5009/gnl16503.

In Vitro Activity of Diphenyleneiodonium Toward Multidrug-Resistant Helicobacter pylori Strains

Free PMC article

In Vitro Activity of Diphenyleneiodonium Toward Multidrug-Resistant Helicobacter pylori Strains

Jun-Won Chung et al. Gut Liver. .
Free PMC article


Background/aims: The increased resistance of Helicobacter pylori to antibiotics has increased the need to develop new treatments for this bacterium. The aim of our study was to identify new drugs with anti-H. pylori activity.

Methods: We screened a small molecule library-the library of pharmacologically active compounds (LOPAC), which includes 1,280 pharmacologically active compounds-to identify inhibitors of H. pylori growth. The minimal inhibitory concentrations (MICs) of antibiotics against multidrug-resistant H. pylori strains were determined using the agar dilution method.

Results: We identified diphenyleneiodonium (DPI) as a novel anti-H. pylori agent. The MIC values for DPI were <0.03 µg/mL against all tested H. pylori strains. DPI also exhibited strong antibacterial activity against common gram-negative and gram-positive pathogenic bacteria.

Conclusions: DPI may be a candidate anti-H. pylori drug for future development.

Keywords: Anti-bacterial agents; Diphenyleneiodonium; Drug resistance, multiple; Helicobacter pylori; Minimal inhibitory concentration.

Conflict of interest statement


No potential conflict of interest relevant to this article was reported.


Fig. 1
Fig. 1
Flow chart showing the selection of anti-Helicobacter pylori agents. LOPAC, library of pharmacologically active compounds; NADPH, nicotinamide adenine dinucleotide phosphate; DPI, diphenyleneiodonium.

Similar articles

See all similar articles

Cited by 2 articles


    1. Hentschel E, Brandstätter G, Dragosics B, et al. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med. 1993;328:308–312. doi: 10.1056/NEJM199302043280503. - DOI - PubMed
    1. Suerbaum S, Josenhans C. Helicobacter pylori evolution and phenotypic diversification in a changing host. Nat Rev Microbiol. 2007;5:441–452. doi: 10.1038/nrmicro1658. - DOI - PubMed
    1. Chung JW, Lee GH, Han JH, et al. The trends of one-week first-line and second-line eradication therapy for Helicobacter pylori infection in Korea. Hepatogastroenterology. 2011;58:246–250. - PubMed
    1. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010;59:1143–1153. doi: 10.1136/gut.2009.192757. - DOI - PubMed
    1. Gisbert JP, Calvet X. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. Aliment Pharmacol Ther. 2011;34:604–617. doi: 10.1111/j.1365-2036.2011.04770.x. - DOI - PubMed

MeSH terms